Thoma Bravo has bought and merged two drug diversion tech companies —Bluesight and Medacist — Thoma Bravo partner Carl Press tells Axios exclusively.
Why it matters: Drug diversion — the illegal distribution or abuse of prescription drugs — costs the health care industry more than $70 billion per year.
